Trump fast-tracks psychedelic research

The White House has directed the FDA to expedite the review of psychedelic-based therapies, including LSD and psilocybin.

The executive order provides $50 million for studies into ibogaine, a plant-based psychedelic derived from a Central African shrub.

While veteran groups have praised the initiative as a potential breakthrough for trauma treatment, some health experts warn of serious heart risks associated with these substances.

The administration's shift in policy marks a significant departure from traditional drug enforcement priorities to address the growing mental health crisis.